Risks from laws, regulations and drug price revisions spanning the Group's business segments
First written in FY2016. 20 of 22 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「On 2 April 2024, the ministerial ordinance partially amending the Ordinance for Enforcement of the Act on the Securing of Safety and the Optimization of Transactions of Liquefied Petroleum Gas was promulgated.」
The company continues to disclose specific new regulations concerning LPG commercial practices, fee systems and information provision. - FY2024WorsenedAnnual report
「On 2 April 2024, the ministerial ordinance partially amending the Ordinance for Enforcement of the Act on the Securing of Safety and the Optimization of Transactions of Liquefied Petroleum Gas was promulgated. The ordinance establishes new rules to optimize transactions and increase fee transparency by correcting commercial practices in the LPG industry. Its main amendments concern restrictions on excessive sales activities, thorough implementation of a three-part fee structure, and the provision of information on LPG fees and other matters.」
In addition to the existing risks from amendments to laws and regulations and regulatory changes, the company discloses specific new regulations concerning LPG commercial practices, fee systems and information provision. - FY2023RestatedAnnual report
「Amendments to these laws and regulations, regulatory changes, and drug price revisions could affect the Group's results.」
Amendments to laws and regulations, regulatory changes and drug price revisions related to each business continue to be identified as risks. - FY2023-Q3RestatedAnnual report
「During the cumulative third quarter of the current fiscal year, there were no material changes in the occurrence of major risks that management recognizes could have a material impact on the financial position and cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in this quarterly report, or in the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing major risks, including amendments to laws and regulations and drug price revisions. - FY2023-Q1RestatedAnnual report
「During the cumulative first quarter of the current fiscal year, there were no material changes in the occurrence of major risks that management recognizes could have a material impact on the financial position and cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in this quarterly report, or in the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing major risks, including amendments to laws and regulations and drug price revisions. - FY2021-Q3RestatedAnnual report
「During the cumulative third quarter of the current fiscal year, there were no material changes in the occurrence of major risks that management recognizes could have a material impact on the financial position and cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in this quarterly report, or in the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in its major business and other risks, including amendments to laws and regulations and drug price revisions. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter of the current fiscal year, there were no material changes in the occurrence of major risks that management recognizes could have a material impact on the financial position and cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in this quarterly report, or in the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in its major business and other risks, including amendments to laws and regulations and drug price revisions. - FY2021-Q1RestatedAnnual report
「During the cumulative first quarter of the current fiscal year, there were no material changes in the occurrence of major risks that management recognizes could have a material impact on the financial position and cash flows of the consolidated companies, among the matters concerning the business and accounting conditions described in this quarterly report, or in the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing major risks, including amendments to laws and regulations and drug price revisions. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing business and other risks, including amendments to laws and regulations and drug price revisions. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing business and other risks, including amendments to laws and regulations and drug price revisions. - FY2020-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing business and other risks, including amendments to laws and regulations and drug price revisions. - FY2019-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing business and other risks, including amendments to laws and regulations and drug price revisions. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing business and other risks, including amendments to laws and regulations and drug price revisions. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing business and other risks, including amendments to laws and regulations and drug price revisions. - FY2018RestatedAnnual report
「Amendments to these laws and regulations, regulatory changes, and drug price revisions could affect results.」
Amendments to laws and regulations, regulatory changes and drug price revisions related to each business continue to be identified as risks. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing business and other risks, including amendments to laws and regulations and drug price revisions. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing business and other risks, including amendments to laws and regulations and drug price revisions. - FY2017RestatedAnnual report
「Amendments to these laws and regulations, regulatory changes, and drug price revisions could affect results.」
Amendments to laws and regulations, regulatory changes and drug price revisions related to each business continue to be identified as risks. - FY2017-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing business and other risks, including amendments to laws and regulations and drug price revisions. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing business and other risks, including amendments to laws and regulations and drug price revisions. - FY2017-Q1RestatedAnnual report
「There have been no material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes in its existing business and other risks, including laws, regulations and drug price revisions. - FY2016First statedAnnual report
「Amendments to these laws and regulations, regulatory changes, and drug price revisions could affect results.」
The company identifies amendments to laws and regulations and drug price revisions concerning safety, food products and pharmaceutical affairs in the LPG, Aqua, and Medical and Industrial Gases businesses as risks.